Dr. O'Sullivan on Safety Profile of Radium-223

Joe OSullivan, MD
Published: Wednesday, Dec 16, 2015



Joe O'Sullivan, MD, clinical professor, School of Medicine, Dentistry and Biomedical Sciences, Centre for Cancer Research and Cell Biology, at Queen’s University Belfast, discusses toxicities associated with radium-223 dichloride for patients with metastatic castration-resistant prostate cancer.

Toxicities that were observed in patients enrolled in the ALSYMPCA trial as well as the expanded access program associated with radium-223 were similar, O’Sullivan says. This included a 5% to 6% rate of grade 3 thrombocytopenia, though this is generally reversible. Also reported were low rates anemia or neutropenia.

Non-hematologic toxicities include diarrhea, O’Sullivan adds.
 


Joe O'Sullivan, MD, clinical professor, School of Medicine, Dentistry and Biomedical Sciences, Centre for Cancer Research and Cell Biology, at Queen’s University Belfast, discusses toxicities associated with radium-223 dichloride for patients with metastatic castration-resistant prostate cancer.

Toxicities that were observed in patients enrolled in the ALSYMPCA trial as well as the expanded access program associated with radium-223 were similar, O’Sullivan says. This included a 5% to 6% rate of grade 3 thrombocytopenia, though this is generally reversible. Also reported were low rates anemia or neutropenia.

Non-hematologic toxicities include diarrhea, O’Sullivan adds.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Clinical Interchange™: Translating Research to Inform Changing Paradigms: Assessment of Emerging Immuno-Oncology Strategies and Combinations across Lung, Head and Neck, and Bladder CancersOct 31, 20182.0
35th Annual Chemotherapy Foundation Symposium: Innovative Cancer Therapy for Tomorrow® Clinical Vignette SeriesJan 31, 20192.0
Publication Bottom Border
Border Publication
x